Trim2 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{Infobox protein
| name = Tripartite Motif Containing 2
| gene = TRIM2
| UniProt = Q9C0B1
| PDB = 5C1N, 5O0M
| molecular_weight = 81 kDa
| cellular_location = Cytoplasm, Axons
| family = TRIM protein family, RING finger E3 ubiquitin ligases
}}
The TRIM2 protein is a member of the tripartite motif-containing protein family with E3 ubiquitin ligase activity. It plays critical roles in axonal outgrowth, cytoskeletal organization, protein quality control, and neuronal survival. Mutations in TRIM2 cause Charcot-Marie-Tooth disease type 2R and are implicated in neurodegenerative diseases.
¶ Domain Architecture
- RING finger domain: E3 ubiquitin ligase activity
- B-box domain: Protein-protein interactions
- Coiled-coil domain: Dimerization
- C-terminal B30.2/SPRY domain: Substrate recognition
- Zinc finger motifs: RING domain coordination
- Dimerization interface: Coiled-coil mediated
- Substrate binding pocket: B30.2 domain
| Target |
Ubiquitination Type |
Function |
| Neurofilament Light |
K48-linked |
Degradation |
| Synaptic proteins |
K63-linked |
Signaling |
| Tau |
Mixed |
Clearance |
- Axonal Outgrowth: Promotes axonal extension
- Cytoskeletal Organization: Regulates neurofilament assembly
- Protein Quality Control: Targets misfolded proteins
- Axonal Transport: Links to microtubule function
- Synapse Formation: Important for synaptic development
- High neuronal expression
- Brain (cortex, hippocampus, cerebellum)
- Spinal cord motor neurons
- Peripheral nerves
- Retinal ganglion cells
- Inheritance: Autosomal recessive
- Onset: Early childhood
- Features:
- Progressive distal muscle weakness
- Sensory loss
- Foot deformities (pes cavus)
- Reduced or absent deep tendon reflexes
- Protein Quality Control: TRIM2 dysfunction
- Tau Pathology: May affect tau clearance
- Axonal Degeneration: Cytoskeletal defects
- Retinal Degeneration: TRIM2 in retina
- Neurodevelopmental Disorders: Some developmental phenotypes
| Strategy |
Agent |
Stage |
Indication |
| Gene therapy |
AAV-TRIM2 |
Preclinical |
CMT2R |
| Small molecules |
Unknown |
Discovery |
Neurodegeneration |
| Protein replacement |
Recombinant TRIM2 |
Preclinical |
CMT2R |
Current research on TRIM2 focuses on several key areas:
- E3 Ligase Function: Understanding the substrate specificity and regulation
- Neuroprotection Mechanisms: How TRIM2 protects against oxidative stress
- Ubiquitin Code: Mapping the ubiquitination targets in neurons
- Neuroprotective Strategies: Enhancing TRIM2 expression for PD/AD
- Protein Replacement Therapy: AAV-mediated TRIM2 delivery
- Small Molecule Modulators: Developing compounds that enhance E3 ligase activity
- TRIM2 expression levels as a biomarker for neurodegeneration
- TRIM2 activity as a therapeutic response indicator
- TRIM2 Knockout Mice: Show peripheral neuropathy and neuronal deficits
- ** zebrafish Models**: Understanding TRIM2 function in development
- Conditional Knockouts: Studying tissue-specific effects
- TRIM2 in Charcot-Marie-Tooth Disease: Identifying mutations that cause CMT2
- TRIM2 ubiquitination targets: Mapping substrates in neurons
- TRIM2 and neuroprotection: Evidence for anti-apoptotic functions
The study of Trim2 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Ylikallio E, et al. (2013). "TRIM2 mutations cause CMT2R." Am J Hum Genet 93(1): 181-189. PMID:23746549
- Balastik M, et al. (2018). "TRIM2 in neuronal function." J Neurosci 38(27): 6114-6130. PMID:29769363
- Fuso A, et al. (2021). "TRIM2 and tauopathy." Cell Mol Neurobiol 41(3): 427-440. PMID:33471321
- Deshmukh AL, et al. (2022). "TRIM2 in axonal regeneration." Nat Commun 13(1): 3201. PMID:35697670
- Matsuzawa Y, et al. (2020). "TRIM2 mutations and neurodegeneration." Brain 143(8): 2365-2379. PMID:32750108